Compound: norepinephrine
SMILES: Oc1c(O)ccc(c1)[C@@H](O)CN
InChIKey: SFLSHLFXELFNJZ-QMMMGPOBSA-N
Synonyms: norepinephrine, L-Noradrenaline, Levarterenol, Arterenol, L-Norepinephrine, (R)-Noradrenaline, (-)-Norepinephrine, (-)-NORADRENALINE, L-arterenol, (-)-Arterenol, (R)-Norepinephrine, 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol, Levonoradrenaline, Sympathin E, Levonorepinephrine, (R)-(-)-Norepinephrine, Norepirenamine, (R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol, Noradrenalin, norepinephrinum, Noradrenalinum, Norartrinal, Nor adrenalin, Nor-Epirenan, norepinefrina, Noradrenalina, L-3,4-dihydroxyphenylethanolamine, D-(-)-Noradrenaline, l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol, (-)-alpha-(Aminomethyl)protocatechuyl alcohol, L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol, 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol, X4W3ENH1CV, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-, NSC-757246, DTXSID5023378, DTXCID203378, CHEBI:18357, 4-((1R)-2-Amino-1-hydroxyethyl)-1,2-benzenediol, 4-((1R)-2-amino-1-hydroxyethyl)benzene-1,2-diol, noradranalinum, noradrAnaline, Norepinephrine 1530, RefChem:6074, (-)-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol, C01CA03, Norepinephrin d-Tartrate (1:1), 200-096-6, (2R)-2-(3,4-dihydroxyphenyl)-2-hydroxyethanaminium, noradrenaline, 51-41-2, Adrenor, Levonor, Levoarterenol, l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol, (-)-(R)-Norepinephrine, 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-, MFCD00025592, Norepinephrine (INN), CHEMBL1437, 4-[(1R)-2-amino-1-hydroxy-ethyl]benzene-1,2-diol, Benzyl alcohol, alpha-(aminomethyl)-3,4-dihydroxy-, (-)-, Levarterenolo, Noreinefrina, Levarterenolo [DCIT], Noradrenalina [Italian], Noradrenalin, l-, NOREPINEPHRINE [INN], d-Arterenol, Noreinefrina [INN-Spanish], Norepinephrinum [INN-Latin], Nor-adrenaline, (+)-Noradrenaline, Nor adrenalin (TN), Noradrenaline (JP15), EINECS 200-096-6, UNII-X4W3ENH1CV, (-)-Arterenol free base, Norepinephrine Noradrenalin, 1,2-Benzenediol, 4-((1R)-2-amino-1-hydroxyethyl)-, BRN 4231961, Norephinephrine, 51-41-2 (free base), R-norepinephrine, DermX, Norepinephrine [INN:BAN:JAN], HSDB 7772, E5E, (R)-4-(2-Amino-1-hydroxyethyl)benzene-1,2-diol, ALBB-006229, (?)-Norepinephrine, Spectrum_001009, Noradrenaline (JP18), Spectrum2_001064, Spectrum3_000520, Spectrum4_000078, Spectrum5_001068, Norepinephrine (Standard), bmse000404, 1,2-Benzenediol,4-(2-amino-1-hydroxyethyl)-, NORADRENALINE [JAN], NOREPINEPHRINE [MI], SCHEMBL2609, BSPBio_002079, GTPL505, KBioGR_000635, KBioSS_001489, NOREPINEPHRINE [HSDB], MLS006010883, DivK1c_000230, NORADRENALINE [MART.], NOREPINEPHRINE [VANDF], SPECTRUM1500436, SPBio_001048, Levarterenol;Levophed;Arterenol, 1,2-Benzenediol, 4-((R)-2-amino-1-hydroxyethyl)-, orb1300117, orb3141108, SGCUT00123, NOREPINEPHRINE [WHO-DD], SCHEMBL29399946, HMS500L12, KBio1_000230, KBio2_001489, KBio2_004057, KBio2_006625, KBio3_001579, D53D5E3A-2360-4CA9-8031-6C2CD4062FD5, NINDS_000230, HMS1920B08, HMS2089E18, HMS2091J08, HMS3887I07, Pharmakon1600-01500436, to_000024, Tox21_301944, BDBM50029051, CCG-40104, EBC-26125, HY-13715R, MSK000564, NOREPINEPHRINE [USP IMPURITY], NSC757246, PDSP1_001111, PDSP2_001095, s9507, STK503776, AKOS006345192, AKOS015854572, DB00368, FN34820, NSC 757246, SDCCGSBI-0050082.P004, Adrenaline EP Impurity B; Noradrenaline, CAS-51-41-2, IDI1_000230, NCGC00159406-03, NCGC00159406-04, NCGC00159406-05, NCGC00159406-06, NCGC00159406-07, NCGC00159406-08, NCGC00159406-09, NCGC00159406-10, NCGC00159406-11, NCGC00159406-17, NCGC00255328-01, AS-56654, HY-13715, SMR000058585, (-)-Norepinephrine, >=98%, crystalline, SBI-0050082.P003, ADRENALINE IMPURITY B [EP IMPURITY], CS-0007744, ethanol, 2-amino-1-(3,4-dihydroxyphenyl)-, NS00008449, A12589, C00547, D00076, EN300-378087, AB00052424-06, AB00052424_07, AB00052424_08, F828565, Q186242, ADRENALINE TARTRATE IMPURITY B [EP IMPURITY], (1R)-2-AMINO-1-(3,4-DIHYDROXYPHENYL)ETHANOL, BRD-K87349682-001-04-9, BRD-K87349682-347-02-0, BRD-K87349682-347-03-8, (-)-.ALPHA.-(AMINOMETHYL)-3,4-DIHYDROXYBENZYL ALCOHOL, 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-, Benzyl alcohol, .alpha.-(aminomethyl)-3,4-dihydroxy-, (+)-, 1,2-BENZENEDIOL, 4-(2-AMINO-1-HYDROXYETHYL)-, (R)-(R-(R*,R*))-2,3-DIHYDROXYBUTANEDIOATE, 65277-62-5
Theoretical properties:
molecular_formula: C8H11NO3
molecular_weight: 169.18 g/mol
exact_mass: 169.07389321 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 2
heavy_atom_count: 12
topological_polar_surface_area: 86.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Colorless microcrystals
color: Colorless microcrystals
solubility: Slightly soluble in water, ethanol, diethyl ether; very soluble in alkali, dilute hydrochloric acid
Descriptions:
{"pubchem": "(R)-noradrenaline is the R-enantiomer of noradrenaline. It has a role as a neurotransmitter, a sympathomimetic agent, an alpha-adrenergic agonist, a vasoconstrictor agent and a mouse metabolite. It is a conjugate base of a (R)-noradrenaline(1+). It is an enantiomer of a (S)-noradrenaline.", "chebi": "The <i>R</i>-enantiomer of noradrenaline.", "chembl": "NOREPINEPHRINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Norepinephrine (NE), also called noradrenaline (NA) or noradrenalin, is an organic chemical in the catecholamine family that functions in the brain and body as a hormone, neurotransmitter and neuromodulator. The name \"norepinephrine\" (from Ancient Greek \u1f10\u03c0\u1fd0\u0301 (ep\u00ed), \"upon\", and \u03bd\u03b5\u03c6\u03c1\u03cc\u03c2 (nephr\u00f3s), \"kidney\") is usually preferred in the United States, whereas \"noradrenaline\" (from Latin ad, \"near\", and ren, \"kidney\") is more commonly used in the United Kingdom and the rest of the world. \"Norepinephrine\" is also the international nonproprietary name given to the drug. Regardless of which name is used for the substance itself, parts of the body that produce or are affected by it are referred to as noradrenergic.\nThe general function of norepinephrine is to mobilize the brain and body for action. Norepinephrine release is lowest during sleep, rises during wakefulness, and reaches much higher levels during situations of stress or danger, in the so-called fight-or-flight response. In the brain, norepinephrine increases arousal and alertness, promotes vigilance, enhances formation and retrieval of memory, and focuses attention; it also increases restlessness and anxiety. In the rest of the body, norepinephrine increases heart rate and blood pressure, triggers the release of glucose from energy stores, increases blood flow to skeletal muscle, reduces blood flow to the gastrointestinal system, and inhibits voiding of the bladder and gastrointestinal motility.\nIn the brain, noradrenaline is produced in nuclei that are small yet exert powerful effects on other brain areas. The most important of these nuclei is the locus coeruleus, located in the pons. Outside the brain, norepinephrine is used as a neurotransmitter by sympathetic ganglia located near the spinal cord or in the abdomen, as well as Merkel cells located in the skin. It is also released directly into the bloodstream by the adrenal glands. Regardless of how and where it is released, norepinephrine acts on target cells by binding to and activating adrenergic receptors located on the cell surface.\nA variety of medically important drugs work by altering the actions of noradrenaline systems. Noradrenaline itself is widely used as an injectable drug for the treatment of critically low blood pressure. Stimulants often increase, enhance, or otherwise act as agonists of norepinephrine. Drugs such as cocaine and methylphenidate act as reuptake inhibitors of norepinephrine, as do some antidepressants, such as those in the SNRI class. One of the more notable drugs in the stimulant class is amphetamine, which acts as a dopamine and norepinephrine analog, reuptake inhibitor, as well as an agent that increases the amount of global catecholamine signaling throughout the nervous system by reversing transporters in the synapses. Beta blockers, which counter some of the effects of noradrenaline by blocking beta-adrenergic receptors, are sometimes used to treat glaucoma, migraines and a range of cardiovascular diseases. \u03b21Rs preferentially bind epinephrine, along with norepinephrine to a lesser extent and mediates some of their cellular effects in cardiac myocytes such as increased positive inotropy and lusitropy. \u03b2-blockers exert their cardioprotective effects through decreasing oxygen demand in cardiac myocytes; this is accomplished via decreasing the force of contraction during systole (negative inotropy) and decreasing the rate of relaxation during diastole (negative lusitropy), thus reducing myocardial energy demand which is useful in treating cardiovascular disorders accompanied by inadequate myocardial oxygen supply. Alpha blockers, which counter the effects of noradrenaline on alpha-adrenergic receptors, are occasionally used to treat hypertension and psychiatric conditions. Alpha-2 agonists often have a sedating and antihypertensive effect and are commonly used as anesthesia enhancers in surgery, as well as in treatment of drug or alcohol dependence. For reasons that are still unclear, some Alpha-2 agonists, such as guanfacine, have also been shown to be effective in the treatment of anxiety disorders and ADHD. Many important psychiatric drugs exert strong effects on noradrenaline systems in the brain, resulting in effects that may be helpful or harmful.\n\n"}